[en] Neprilysin, a widely expressed peptidase upregulated in type 2 diabetes, is capable of cleaving and inactivating the insulinotropic glucagon-like peptide-1 (GLP-1). Like dipeptidyl peptidase-4 (DPP-4), inhibition of neprilysin activity under diabetic conditions is associated with increased active GLP-1 levels and improved glycemic control. While neprilysin expression has been demonstrated in islets, its local contribution to GLP-1-mediated insulin secretion remains unknown. We investigated in vitro whether islet neprilysin inhibition enhances insulin secretion in response to glucose and/or exogenous GLP-1, and whether these effects are mediated by GLP-1 receptor (GLP-1R). Further, we compared the effect of neprilysin versus DPP-4 inhibition on insulin secretion. Isolated islets from wild-type (Glp1r(+/+)) and GLP-1 receptor knockout (Glp1r(-/-)) mice were incubated with or without the neprilysin inhibitor thiorphan and/or the DPP-4 inhibitor sitagliptin for 2.5 hours. During the last hour, insulin secretion was assessed in response to 2.8 mmol/l or 20 mmol/l glucose alone or plus exogenous active GLP-1. In Glp1r(+/+) islets, neprilysin inhibition enhanced 2.8 mmol/l and 20 mmol/l glucose- and GLP-1-mediated insulin secretion to the same extent as DPP-4 inhibition. These effects were blunted in Glp1r(-/-) islets. In conclusion, inhibition of islet neprilysin in vitro increases glucose-mediated insulin secretion in a GLP-1R-dependent manner and enhances the insulinotropic effect of exogenous active GLP-1. Thus, neprilysin inhibitors may have therapeutic potential in type 2 diabetes by preserving islet-derived and circulating active GLP-1 levels.
Disciplines :
Endocrinology, metabolism & nutrition
Author, co-author :
Esser, Nathalie ; University of Washington - UW > Department of Medicine > Division of Metabolism, Endocrinology and Nutrition
Barrow, Breanne M.
Choung, Edwina
Shen, Nancy J.
Zraika, Sakeneh; University of Washington - UW > Department of Medicine > Division of Metabolism, Endocrinology and Nutrition
Language :
English
Title :
Neprilysin inhibition in mouse islets enhances insulin secretion in a GLP-1 receptor dependent manner.
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
Bibliography
Standeven KF, Hess K, Carter AM, Rice GI, Cordell PA, Balmforth AJ, Lu B, Scott DJ, Turner AJ, Hooper NM, et al. Neprilysin, obesity and the metabolic syndrome. Int J Obes. 2011;35:1031–1040. doi:10.1038/ijo.2010.227.
Willard JR, Barrow BM, Zraika S., Improved glycaemia in high-fat-fed neprilysin-deficient mice is associated with reduced DPP-4 activity and increased active GLP-1 levels. Diabetologia. 2017;60:.701–708. doi:10.1007/s00125-016-4172-4.
Zraika S, Koh DS, Barrow BM, Lu B, Kahn SE, Andrikopoulos S., Neprilysin deficiency protects against fat-induced insulin secretory dysfunction by maintaining calcium influx. Diabetes. 2013;62:.1593–1601. doi:10.2337/db11-1593.
Hupe-Sodmann K, McGregor GP, Bridenbaugh R, Göke R, Göke B, Thole B,T, Hole H, Zimmermann B, Voigt K. Characterisation of the processing by human neutral endopeptidase 24.11 of GLP-1(7–36) amide and comparison of the substrate specificity of the enzyme for other glucagon-like peptides. Regul Pept. 1995;58:149–156. doi:10.1016/0167-0115(95)00063-H.
Plamboeck A, Holst JJ, Carr RD, Deacon CF. Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig. Diabetologia. 2005;48:1882–1890. doi:10.1007/s00125-005-1847-7.
Vodovar N, Nougué H, Launay JM, Socal AC, Logeart D. Sacubitril/valsartan in PARADIGM-HF. Lancet Diabetes Endocrinol. 2017;5:.495–496. doi:10.1016/S2213-8587(17)30177-8.
Chambers AP, Sorrell JE, Haller A, Roelofs K, Hutch CR, Kim KS, Gutierrez-Aguilar R, Li B, Drucker DJ, D’Alessio DA, et al. The role of pancreatic preproglucagon in glucose homeostasis in mice. Cell Metab. 2017;25:927–934.e3. doi:10.1016/j.cmet.2017.02.008.
Omar BA, Liehua L, Yamada Y, Seino Y, Marchetti P, Ahrén B. Dipeptidyl peptidase 4 (DPP-4) is expressed in mouse and human islets and its activity is decreased in human islets from individuals with type 2 diabetes. Diabetologia. 2014;57:.1876–1883. doi:10.1007/s00125-014-3299-4.
Seferovic JP, Claggett B, Seidelmann SB, Seely EW, Packer M, Zile MR, Rouleau JL, Swedberg K, Lefkowitz M, Shi VC, et al. Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial. Lancet Diabetes Endocrinol. 2017;5:333–340. doi:10.1016/S2213-8587(17)30087-6.
Udell JA, Cavender MA, Bhatt DL, Chatterjee S, Karkouh ME, Scirica BM. Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol. 2015;3:.356–366. doi:10.1016/S2213-8587(15)00044-3.
Simonsen L, Pilgaard S, Carr RD, Kanstrup AB, Holst JJ, Deacon CF. Inhibition of neutral endopeptidase 24.11 does not potentiate the improvement in glycemic control obtained with dipeptidyl peptidase-4 inhibition in diabetic Goto–kakizaki rats. Horm Metab Res. 2009;41:.851–853. doi:10.1055/s-0029-1225609.
Cantini G, Mannucci E, Luconi M. Perspectives in GLP-1 research: new targets, new receptors. Trends Endocrinol Metab. 2016;27:.427–438. doi:10.1016/j.tem.2016.03.017.
Similar publications
Sorry the service is unavailable at the moment. Please try again later.
This website uses cookies to improve user experience. Read more
Save & Close
Accept all
Decline all
Show detailsHide details
Cookie declaration
About cookies
Strictly necessary
Performance
Strictly necessary cookies allow core website functionality such as user login and account management. The website cannot be used properly without strictly necessary cookies.
This cookie is used by Cookie-Script.com service to remember visitor cookie consent preferences. It is necessary for Cookie-Script.com cookie banner to work properly.
Performance cookies are used to see how visitors use the website, eg. analytics cookies. Those cookies cannot be used to directly identify a certain visitor.
Used to store the attribution information, the referrer initially used to visit the website
Cookies are small text files that are placed on your computer by websites that you visit. Websites use cookies to help users navigate efficiently and perform certain functions. Cookies that are required for the website to operate properly are allowed to be set without your permission. All other cookies need to be approved before they can be set in the browser.
You can change your consent to cookie usage at any time on our Privacy Policy page.